# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Julius Caesar (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-AC001-SYN
- Date: 2026-10-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lucius Fairbanks-Okonkwo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Ten-week review: seizure control, lipids, blood pressure, and driving. **S**

## History of present illness

Julius Caesar returns ten weeks after starting levetiracetam, atorvastatin, and aspirin, and six weeks after amlodipine was added. He has had no seizure, spell, or confused awakening, and has missed no doses. He has had slight ankle swelling in the evenings, which he does not mind. His home readings are 118 to 128 over 72 to 80. He has no muscle aches, bleeding, or bruising, and his mood is good. He asks when he can drive again and whether he can stop any of the medicines in time. **S**

| Element | Detail |
|---|---|
| Seizures | None for ten weeks |
| Home blood pressure | 118 to 128 over 72 to 80 |
| Side effects | Slight evening ankle swelling on amlodipine |
| Questions | Driving; how long the medicines are needed |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Slight evening ankle swelling; no chest pain or breathlessness |
| Musculoskeletal | Negative | No muscle aches |
| Neurological | Negative | No spell or new symptom |
| Psychiatric | Negative | Mood good; PHQ-9 3 |

4 systems reviewed. **S**

## Current medications

- Lisinopril 10 mg oral tablet, one tablet by mouth daily **S**
- Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth at bedtime **S**
- Aspirin 81 mg delayed-release tablet, one tablet by mouth daily **S**
- Amlodipine 5 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/76 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 75 kg; BMI 22.6 kg/m². All vital signs are synthetic.

Total cholesterol: 136 mg/dL; HDL cholesterol: 46 mg/dL; LDL cholesterol: 68 mg/dL; Triglycerides: 110 mg/dL; ALT: 34 U/L; PHQ-9: 3. All results are synthetic.

## Change since baseline

- Total cholesterol: 236 mg/dL (high) at baseline, 136 mg/dL at this visit **S**
- HDL cholesterol: 44 mg/dL at baseline, 46 mg/dL at this visit **S**
- LDL cholesterol: 158 mg/dL (high) at baseline, 68 mg/dL at this visit **S**
- Triglycerides: 170 mg/dL (high) at baseline, 110 mg/dL at this visit **S**
- ALT: 28 U/L at baseline, 34 U/L at this visit **S**
- PHQ-9: 3 at baseline, 3 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Cardiovascular | Regular rhythm; blood pressure 124/76 mmHg; trace ankle edema |
| Neurological | No focal deficit |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Focal epilepsy on levetiracetam** (G40.209). Seizure-free for ten weeks on 500 mg twice daily; mood good (PHQ-9 3, item 9 scored 0). With a structural cause the risk of recurrence stays high, so treatment is long term; any later trial off medicine would be a decision with his neurologist after at least two seizure-free years. **S**
   - Continue levetiracetam 500 mg twice daily.
   - Neurology review at six months.
   - Driving: not before the seizure-free period that state law requires (six months in this state) and his neurologist's clearance.
2. **Chronic left temporal cortical infarct** (I69.398). LDL 68 mg/dL, below 70, and ALT 34 U/L on atorvastatin 80 mg. Blood pressure at target. No new symptoms. **S**
   - Continue aspirin 81 mg and atorvastatin 80 mg.
   - Lipid panel every 6 to 12 months.
3. **Hypertension** (I10). 124/76 mmHg in the office and at target at home on lisinopril and amlodipine; trace edema is tolerable. **S**
   - Continue both medicines.
   - Potassium and creatinine once a year.
4. **Hyperlipidemia** (E78.5). LDL fell from 158 to 68 mg/dL. **S**
   - Continue atorvastatin 80 mg.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (target below 130/80 mmHg) | Every visit | Completed today | 124/76 mmHg; home 118 to 128 over 72 to 80 |
| Laboratory | Lipid panel after starting a statin | 4 to 12 weeks after starting, then every 3 to 12 months | Completed today | LDL 68 mg/dL (target below 70); total cholesterol 136, HDL 46, triglycerides 110 mg/dL |
| Medication safety | Statin tolerance and liver tests | At the first lipid check, then with symptoms | Completed today | ALT 34 U/L; no muscle aches |
| Survey | Depression screen (PHQ-9) | Periodically, at least yearly | Completed today | 3; item 9 scored 0 |
| Laboratory | Potassium and creatinine | Yearly on an ACE inhibitor once stable | Up to date | Normal after the start; next in a year |
| Laboratory | Diabetes screen | Periodically after a stroke without diabetes | Up to date | HbA1c 5.6 percent at intake; repeat yearly |
| Medication safety | Influenza vaccination | Yearly | Up to date | Given at the preventive visit three weeks ago |
| Survey | Cognitive screen (MoCA) | In the first year, then periodically | Up to date | 28 of 30 six weeks ago |
| Medication safety | Antithrombotic adherence and bleeding | Every visit | Completed today | Aspirin daily; no bleeding |
| Medication safety | Antiseizure medicine: seizures, adherence, and side effects | Every visit | Completed today | No seizure for ten weeks; no side effects now |
| Examination | Fall risk | Every visit | Completed today | No falls |
| Examination | Weight and BMI | Every visit | Completed today | 75.0 kg; BMI 22.6 |
| Self-management | Tobacco, alcohol, physical activity, and diet | Every visit | Completed today | Diet and walking kept up; alcohol unchanged; never smoker |
| Self-management | Seizure safety and driving | Every visit | Completed today | Not driving; review at six seizure-free months with neurology; riding only with a companion |

## Goal progress

- Cause of the spells established and explained to him by the neurology visit. Outcome by 2026-08-18: Focal epilepsy with a structural vascular cause, from a chronic left temporal cortical infarct; syncope and transient ischemic attack judged unlikely. **S**
- No seizures on levetiracetam through the ten-week review. Outcome by 2026-10-27: No seizure or spell since levetiracetam was started ten weeks ago. **S**
- Office blood pressure below 130/80 mmHg. Outcome by 2026-10-27: 124/76 mmHg on lisinopril 10 mg and amlodipine 5 mg. **S**
- LDL cholesterol below 70 mg/dL on a high-intensity statin. Outcome by 2026-10-27: LDL 68 mg/dL after ten weeks of atorvastatin 80 mg. **S**
- No driving, swimming alone, or riding alone while the seizure-free period is counted, with a written seizure action plan for his staff. Outcome by 2026-10-27: Not driving; a driver and a riding companion arranged; seizure action plan given to his staff. **S**

## Guideline basis

- Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society (2015), American Academy of Neurology and American Epilepsy Society (Neurology)
- Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy (2018), American Academy of Neurology and American Epilepsy Society (Neurology)
- 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2021), American Heart Association and American Stroke Association (Stroke)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Hypertension)
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018), American Heart Association and American College of Cardiology (Circulation)
- CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, hypertension, and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Chronic-care visit in three months; neurology review at six months; lipid panel in six months; next preventive visit in a year. **S**

